stockrowAmphastar Pharmaceuticals, Inc.
AMPH Healthcare Drug Manufacturers Specialty & Generic
Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024.
- Revenue
- +8.22%
- EPS
- +134.2%
- Free cash flow
- −29.4%
- Total debt
- +0.57%
Quarter to September 2026, against a year earlier
Follow AMPH
Alert me
Amphastar Pharmaceuticals, Inc. (AMPH) EV/Sales
As of 5 November 2026, Amphastar Pharmaceuticals, Inc. (AMPH) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 1.5× (May 2026) to 6.4× (August 2023); the current reading is higher than 9% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | (26.31%) |
| FY2024 | 3.0× | (42.60%) |
| FY2023 | 5.2× | 103.99% |
| FY2022 | 2.5× | 5.79% |
| FY2021 | 2.4× | (4.88%) |
| FY2020 | 2.5× | (5.85%) |
| FY2019 | 2.7× | (10.27%) |
| FY2018 | 3.0× | (16.45%) |
| FY2017 | 3.6× | 13.62% |
| FY2016 | 3.1× | 28.99% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.9× | 15.76% |
| Jun 2026 | 1.6× | (1.69%) |
| Mar 2026 | 1.7× | (23.66%) |
| Dec 2025 | 2.2× | 0.95% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PAHC Phibro Animal Health Corporation compare | 1.4× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.6× |
| AMPH Amphastar Pharmaceuticals, Inc. | 2.0× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| CRON Cronos Group Inc. compare | 3.0× |
| HROW Harrow, Inc. compare | 4.3× |
| ALVO Alvotech compare | 8.6× |
| ETON Eton Pharmaceuticals, Inc. compare | 9.4× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)